Boiron S.A.

Boiron manufactures and markets homeopathic medicines. Homeopathic medicines are prepared from vegetable, animal, mineral, or chemical substances, which are diluted. Co. sells three types of products in 59 countries: Non-proprietary homeopathic medicines, OTC family medication specialties, and Other products. There are two large families of homeopathic medicines: Those associated with precise therapeutic indications and dosage, and those that do not mention a therapeutic indication or dosage. Co. supports homeopathy education and training organizations for healthcare professionals. Some of Co.'s brand names include Oscillococcinum®, Stodal®, S?datif PC®, and Coryzalia.
  • TickerBOI
  • ISINFR0000061129
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

Matthieu DRIOL

Short term view - BOIRON SA : The background trend is clearly bearish.

The background trend is clearly bearish. The movement goes on. The next target is at €51.85, then €50.19. Passing €68.90 would question the continuation of the fall.

Matthieu DRIOL

Analyse court terme - BOIRON SA : La tendance de fond est clairement orientée à la baisse.

La tendance de fond est clairement orientée à la baisse. Le mouvement se poursuit. Le prochain objectif est à 51,85 €, puis 50,19 €. Le franchissement de 68,90 € remettrait en cause la suite de la baisse.

Matthieu DRIOL

Short term view - BOIRON SA : The movement goes on.

The background trend is clearly bearish. The movement goes on. The next target is at €51.85, then €50.19. Passing €68.90 would question the continuation of the fall.

Matthieu DRIOL

Analyse court terme - BOIRON SA : Le mouvement se poursuit.

La tendance de fond est clairement orientée à la baisse. Le mouvement se poursuit. Le prochain objectif est à 51,85 €, puis 50,19 €. Le franchissement de 68,90 € remettrait en cause la suite de la baisse.

Matthieu DRIOL

Medium term view - BOIRON SA : The movement goes on.

The background trend is clearly bearish. The movement goes on. The next target is at €51.85, then €41.74. Passing €88.94 would question the continuation of the fall.

Ahmed Ben Salem ...
  • Aurelien Sivignon
  • Baptiste Lebacq
  • Charles Lepetitpas
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Fatma Agnès Hamdani
  • Fehmi Ben Naamane
  • Hana Maalej
  • Harold De Decker
  • Hela Zarrouk
  • Jean Sassus
  • Jean-François Granjon
  • Jeremy Garnier
  • Johanna Jourdain
  • Laurence Hofmann
  • Nicolas David
  • Olivier Lebrun
  • Salma Bouraoui
  • Stephane Houri
  • Steven Gould

ODDO BHF Small & MIDCAP MORNING NEWS - 19/10/2018

...

Christophe-Raphaël Ganet

Boiron : Q3 sales still in poor health (-4.9%) – Prospect of a decline in current operating profit more likely – Forecasts adjusted – TP: € 62 vs € 63

>Q3: -4.9%, lower than we expected - Q3 sales reached € 155.6m, i.e. -4.9% and -4.4% cc.9M sales fell by 2.7% (-1.1% cc).Going forward, Boiron merely said that it expects operating profit in 2018 to be lower than in 2017.Momentum and visibility still mediocre - Our key takeaways from the Q3 figures:1- the Q3 revenue figures show that i/ the momentum was poorer than in the end-June consolidated figures (-1.5% and +0.9% cc), although com...

Ahmed Ben Salem ...
  • Aurelien Sivignon
  • Baptiste Lebacq
  • Charles Lepetitpas
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Fatma Agnès Hamdani
  • Fehmi Ben Naamane
  • Hana Maalej
  • Harold De Decker
  • Hela Zarrouk
  • Jean Sassus
  • Jean-François Granjon
  • Jeremy Garnier
  • Johanna Jourdain
  • Laurence Hofmann
  • Nicolas David
  • Olivier Lebrun
  • Salma Bouraoui
  • Stephane Houri
  • Steven Gould

ODDO BHF Small & MIDCAP MORNING NEWS - 10/19/2018

...

Christophe-Raphaël Ganet

Boiron : CA T3 encore fébrile (-4.9%) – La perspective d’une baisse du ROC se confirme – Prévisions ajustées – OC 62 € vs 63 €

>T3 : -4,9%, sous notre attente - Le CA T3 se monte à 155,6 M€, soit -4,9% et -4,4% à tcc.A 9 mois, le CA recule de 2.7% (-1.1% à tcc).Pour ses perspectives, Boiron indique simplement que pour 2018, son résultat opérationnel « devrait être en recul par rapport à celui de 2017 ».Momentum et visibilité encore médiocres - Notre lecture du T3 s’articule autour des points suivants :les revenus du T3 montrent i/ une détérioration de la tendan...

Christophe-Raphaël Ganet

ODDO : Q3 2018 previews: expensive healthcare

>T3: +9.7%e forecast - After growth of around +10% in H1, our forecasts are for growth in the region of 9.7% in Q3.Growth levels are fairly disparate but we can say that the most robust growth levels will likely come from Ipsen, Sartorius Stedim Biotech and bioMérieux. The weakest growth levels will probably be generated by Guerbet, Boiron and Vétoquinol.Virbac has already reported its Q3 results, these were towards the upper end of the forecast range. Q3 pu...

1 director bought

A director at Boiron bought 441 shares at 68.800EUR and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board me...

Alex Koagne ...
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Jean Sassus
  • Olfa Taamallah
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 10/15/2018

...

Ahmed Ben Salem ...
  • Bruno Cavalier
  • Christophe-Raphaël Ganet
  • Emira Sagaama
  • Jean Sassus
  • Laure Billoret
  • Matthias Desmarais
  • Steven Gould
  • Valentin Pernet
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 10/15/2018

...

Ahmed Ben Salem ...
  • Bruno Cavalier
  • Christophe-Raphaël Ganet
  • Emira Sagaama
  • Jean Sassus
  • Laure Billoret
  • Matthias Desmarais
  • Steven Gould
  • Valentin Pernet
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 15/10/2018

...

Alex Koagne ...
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Jean Sassus
  • Olfa Taamallah
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 15/10/2018

...

Christophe-Raphaël Ganet ...
  • Michael Foundoukidis
  • Sylvain Goyon, CFA
  • Thomas Zlowodzki

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 08/28/2018

The ongoing monetary normalisation by the Fed and the imminent prospect of a similar move by the ECB, amid question marks over the real cyclical position on either side of the Atlantic, will likely put rate trends at the top of investors’ list of concerns. We have thus sought to determine the European sectors and stocks with the most exposure to this theme going forward, using weekly 6-month correlations. For a rate increase, the analysis gives a long position on banks, insurance, oil...

BOIRON SA sees a downgrade to Slightly Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of BOIRON SA (FR), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date July 21, 2017, the closing price was EUR 82.00 and its target price was estimated at EUR 77.84.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Jehanne Leroy

Proxy Report - 17/05/2018

Proxinvest attire l'attention des actionnaires sur deux points importants : Tout d'abord le conseil d'administration a un taux d'indépendance extrêmement faible avec 8,33% d'après Proxinvest. A ce moment-là Proxinvest regrette que la fin des mandats des trois administrateurs renouvelés cette année n'ait pas entrainé un sursaut de la société pour nommer en lieu et place des administrateurs indépendants. Ensuite le manque de communication des rémunérations est un grave manquement de la part de la société qui empêche les actionnaires d'avoir une vision globale des montants en jeu et de l'exigen...

Boiron 2014

​Geol analyses are ESG (Environment, Social, Governance) analyses covering European large caps and small and mid caps, listed or non-listed. Those analyses, based on the ESG risks identified, show the qualitative and quantitative performance of issuers, in a ten-page synthesis.

SRI Quantitative KPIs

Les analyses Gaïa sont des analyses ESG (Environnement, Social, Gouvernance) dediees aux entreprises de tailles intermediaires (PME, ETI) françaises. Elles presentent 120 indicateurs quantitatifs sur les trois derniers exercices.

Matthieu DRIOL

Short term view - BOIRON SA : The background trend is clearly bearish.

The background trend is clearly bearish. The movement goes on. The next target is at €51.85, then €50.19. Passing €68.90 would question the continuation of the fall.

Matthieu DRIOL

Analyse court terme - BOIRON SA : La tendance de fond est clairement orientée à la baisse.

La tendance de fond est clairement orientée à la baisse. Le mouvement se poursuit. Le prochain objectif est à 51,85 €, puis 50,19 €. Le franchissement de 68,90 € remettrait en cause la suite de la baisse.

Matthieu DRIOL

Short term view - BOIRON SA : The movement goes on.

The background trend is clearly bearish. The movement goes on. The next target is at €51.85, then €50.19. Passing €68.90 would question the continuation of the fall.

Matthieu DRIOL

Analyse court terme - BOIRON SA : Le mouvement se poursuit.

La tendance de fond est clairement orientée à la baisse. Le mouvement se poursuit. Le prochain objectif est à 51,85 €, puis 50,19 €. Le franchissement de 68,90 € remettrait en cause la suite de la baisse.

Matthieu DRIOL

Medium term view - BOIRON SA : The movement goes on.

The background trend is clearly bearish. The movement goes on. The next target is at €51.85, then €41.74. Passing €88.94 would question the continuation of the fall.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch